Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CEO Sells $2,339,194.20 in Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CEO Michael Davidson sold 64,708 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $36.15, for a total value of $2,339,194.20. Following the transaction, the chief executive officer owned 459,859 shares in the company, valued at approximately $16,623,902.85. This trade represents a 12.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

NewAmsterdam Pharma Trading Down 2.1%

Shares of NAMS stock traded down $0.73 on Thursday, reaching $34.28. The company had a trading volume of 900,936 shares, compared to its average volume of 634,742. The stock has a market cap of $3.89 billion, a PE ratio of -19.81 and a beta of 0.06. The company has a 50-day moving average of $34.05 and a 200-day moving average of $32.88. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings data on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.23). NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.92 million. Sell-side analysts anticipate that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on NAMS shares. The Goldman Sachs Group raised their price objective on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 2nd. Royal Bank Of Canada increased their price objective on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. Wall Street Zen cut NewAmsterdam Pharma from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of NewAmsterdam Pharma in a research note on Thursday, February 19th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $55.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 6th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, NewAmsterdam Pharma presently has an average rating of “Moderate Buy” and an average price target of $47.00.

Institutional Trading of NewAmsterdam Pharma

Several institutional investors and hedge funds have recently bought and sold shares of NAMS. Atle Fund Management AB grew its stake in shares of NewAmsterdam Pharma by 23.2% in the third quarter. Atle Fund Management AB now owns 193,625 shares of the company’s stock valued at $5,507,000 after buying an additional 36,402 shares in the last quarter. Jennison Associates LLC lifted its stake in NewAmsterdam Pharma by 42.5% in the third quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock valued at $119,407,000 after acquiring an additional 1,252,451 shares during the last quarter. Keybank National Association OH acquired a new stake in NewAmsterdam Pharma in the third quarter valued at $455,000. Franklin Resources Inc. grew its position in shares of NewAmsterdam Pharma by 30.6% in the 2nd quarter. Franklin Resources Inc. now owns 334,212 shares of the company’s stock valued at $6,053,000 after acquiring an additional 78,300 shares during the period. Finally, Frazier Life Sciences Management L.P. increased its stake in shares of NewAmsterdam Pharma by 3.0% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock worth $300,754,000 after purchasing an additional 490,656 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.